Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept


ABSTRACT: Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis, and is an ideal candidate to develop systems to predict who will respond to therapy. A clinical trial of 22 patients with moderate to severe psoriasis treated with alefacept (7.5mg weekly i.v. x12 weeks) was conducted in 2002-2003, as a mechanism of action study. Patients were classified as responders or non-responders to alefacept based on histological criteria. Microarray data from PBMCs of 16 of these patients was analyzed to generate a treatment response classifier. We used a discriminant analysis method that performs sample classification from gene expression data, via nearest shrunken centroid method''. A disease response classifier using 23 genes was created to accurately predict response to alefacept (12.3% error rate in favour of responders). This preliminary study may provide a useful tool to predict response of psoriatic patients with alefacept. Keywords: class prediction Microarray data from 16 patients was analyzed to generate a treatment response classifier. We used a discriminant analysis method that performs sample classification from gene expression data, via nearest shrunken centroid method.

ORGANISM(S): Homo sapiens

SUBMITTER: Mayte Suarez-Farinas 

PROVIDER: E-GEOD-18948 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept.

Suárez-Fariñas Mayte M   Shah Kejal R KR   Haider Asifa S AS   Krueger James G JG   Lowes Michelle A MA  

BMC dermatology 20100212


<h4>Background</h4>Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis, and is an ideal candidate to develop systems to predict who will respond to therapy. A clinical trial of 22 patients with moderate to severe psoriasis treated with alefacept was conducted in 2002-2003, as a mechanism of action study. Patients were classified as responders or non-responders to alefacept based on histological criteria. Results of the original mechanism of action  ...[more]

Similar Datasets

2009-12-01 | GSE18948 | GEO
2015-05-01 | E-GEOD-58431 | biostudies-arrayexpress
2015-05-01 | GSE58431 | GEO
2010-02-05 | GSE19353 | GEO
2010-02-04 | E-GEOD-19353 | biostudies-arrayexpress
2014-08-01 | E-GEOD-43732 | biostudies-arrayexpress
2014-08-01 | GSE43732 | GEO
2009-12-31 | E-GEOD-14671 | biostudies-arrayexpress
2024-07-21 | GSE272173 | GEO
2008-01-01 | GSE6095 | GEO